AR039345A1 - Derivados de acido amino-1h-indol-2-carboxilico 3-sustituidos y de acido amino-benzo(b)-tiofeno-2-carboxilico 3-sustituidos como inhibidores de la expresion del gen de la inteleuquina-4 - Google Patents

Derivados de acido amino-1h-indol-2-carboxilico 3-sustituidos y de acido amino-benzo(b)-tiofeno-2-carboxilico 3-sustituidos como inhibidores de la expresion del gen de la inteleuquina-4

Info

Publication number
AR039345A1
AR039345A1 ARP030101394A ARP030101394A AR039345A1 AR 039345 A1 AR039345 A1 AR 039345A1 AR P030101394 A ARP030101394 A AR P030101394A AR P030101394 A ARP030101394 A AR P030101394A AR 039345 A1 AR039345 A1 AR 039345A1
Authority
AR
Argentina
Prior art keywords
6alkyl
alkyl
amino
phenyl
group
Prior art date
Application number
ARP030101394A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR039345A1 publication Critical patent/AR039345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método de tratamiento de alergia, asma, rinitis, dermatitis, linfomas de células B, tumores, anti-bacterianos, rinovirus o virus respiratorio sincitial (RSV) que comprende administrar a un paciente que se encuentra en necesidad de dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de la fórmula (1), en la cual: X e Y son iguales o diferentes y se seleccionan independientemente del grupo constituido por H, halógeno, nitro, amino, hidroxi, C1-6 alquilo, C2-6-alquenilo, C2-6-alquinilo, C1-6-alcoxi, C1-6-perfluoro-alquilo, C1-6-perfluoroalcoxi, fenilo y bencilo, en las cuales fenilo o bencilo está sustituido opcionalmente con uno o dos sustituyentes cada uno de los cuales se selecciona independientemente de C1-6-alquilo, C1-6-perfluoroalquilo, halógeno, hidroxi o C1-6-perfluoroalquilo o C1-6-perfluoroalcoxi; Z es N-R o S, donde R se selecciona del grupo constituido por H, C1-6 alquilo, C1-6alquilcarbonilo, C1-6alcoxicarbonil-C1-6alquilo, C1-6alquilcarbamoil-C1-6alquilo y C1-6-dialquilcarbamoil-C1-6alquilo; R1 se selecciona del grupo constituido por H, C1-6alquilo, C2-6alquenilo, C2-6alquinilo, C1-6perfluoroalquilo, C3-8cicloalquilo, C3-8cicloalquil-C1-6alquilo, C1-6alcoxi-C1-6alquilo, hidroxi-C1-6alquilo, amino-C1-6alquilo, mono- o di-C1-6-alquil-amino-C1-6alquilo, formilo, C1-6alquilcarbonilo, amino-C1-6alquilcarbonilo, C1-6alcoxicarbonilo, fenilo, difenil-C1-6alquilo y fenil C1-6alquilo, fenilcarbonil-C1-6alquilo, fenoxi-C1-6alquilo, donde fenilo está sustituido opcionalmente con uno o dos sustituyentes cada uno de los cuales se selecciona independientemente de C1-6alquilo, C1-6perfluoroalquilo, halógeno, hidroxi o C1-6perfluoroalquilo o C1-6perfluoroalcoxi; R3 es como se muestra en el grupo de fórmulas (2) en cuyas fórmulas R4 se selecciona del grupo constituido por H, halógeno, nitro, amino, hidroxi, C1-6alquilo, C1-6alcoxi, C1-6perfluoroalquilo, C1-6perfluoroalcoxi, fenilo y bencilo, donde fenilo o bencilo está sustituido opcionalmente con uno o dos sustituyentes seleccionados cada uno independientemente de C1-6 alquilo, C1-6 perfluoroalquilo, halógeno, hidroxi o C1-6perfluoroalquilo o C1-6perfluoroalcoxi, y n es un número entero de 0 a 4; y R2 se selecciona del grupo constituido por H, C1-6 alquilo, C1-6 perfluoroalquilo, perfluoroarilo, indanilo, C1-6-alcoxiC1-6alquilo, C2-6aciloxi-C1-6alquilo, C1-6alcoxicarbonil-C1-6alquilo, C1-6alquilo, C3-8cicloalquilo, C3-8cicloalcoxicarbonil-oxi-C1-6alquilo, adamantiloxicarboniloxi-C1-6alquilo, C3-8cicloalcoxicarbonil-C1-6alquilo, mono- o di-C1-6alquilamino-C1-6alquilo, C3-8azacicloalquil-C1-6-alquilo, mono- o di-C1-6alquilcarbamoil-C1-6alquilo, C3-8azacicloalquilcarboniloxi-C1-6 alquilo, bencilC1-6-alquilcarbamoil-C1-6alquilo, mono- o di-C1-6alquil-carbamoiloxi-C1-6alquilo, C3-8azacicloalquilcarboniloxi-C1-6alquilo, bencilC1-6-alquilcarbamoiloxi-C1-6alquilo, bencilcarbamoiloxi-C1-6alquilo, C1-6alcoxicarbonil-amino-oxo-C1-6alquilo, o un resto seleccionado del grupo de fórmulas (3), en donde R5 es H o C1-6 alquilo, R6 es C1-6 alquilo, fenilo o tolilo, y A es CH2, NH u O, o una de sus sales farmacéuticamente aceptables, opcionalmente en combinación con un vehículo farmacéuticamente aceptable.
ARP030101394A 2002-04-23 2003-04-23 Derivados de acido amino-1h-indol-2-carboxilico 3-sustituidos y de acido amino-benzo(b)-tiofeno-2-carboxilico 3-sustituidos como inhibidores de la expresion del gen de la inteleuquina-4 AR039345A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37530402P 2002-04-23 2002-04-23
GBGB0217920.8A GB0217920D0 (en) 2002-04-23 2002-08-02 Interleukin-4 Gene Expression inhibitors

Publications (1)

Publication Number Publication Date
AR039345A1 true AR039345A1 (es) 2005-02-16

Family

ID=23480336

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101394A AR039345A1 (es) 2002-04-23 2003-04-23 Derivados de acido amino-1h-indol-2-carboxilico 3-sustituidos y de acido amino-benzo(b)-tiofeno-2-carboxilico 3-sustituidos como inhibidores de la expresion del gen de la inteleuquina-4

Country Status (6)

Country Link
US (3) US20040006123A1 (es)
JP (1) JP4746271B2 (es)
KR (2) KR100972304B1 (es)
AR (1) AR039345A1 (es)
GB (1) GB0217920D0 (es)
TW (1) TWI296926B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
US7405300B2 (en) * 2003-09-04 2008-07-29 Aventis Pharmaveuticals Inc. Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US20100197687A1 (en) * 2005-01-19 2010-08-05 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
CN101142185A (zh) * 2005-01-19 2008-03-12 比奥里波克斯公司 用于炎症治疗的吲哚
WO2008042571A2 (en) * 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
US8063094B2 (en) * 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US8786873B2 (en) * 2009-07-20 2014-07-22 General Electric Company Application server for use with a modular imaging system
CN101628842A (zh) * 2009-08-27 2010-01-20 中国人民解放军防化指挥工程学院 烷氧羰基甲氧基作为羧基保护基
US8243882B2 (en) 2010-05-07 2012-08-14 General Electric Company System and method for indicating association between autonomous detector and imaging subsystem
KR101292836B1 (ko) * 2011-03-28 2013-08-05 한국화학연구원 벤조퓨란 또는 벤조싸이오펜 유도체 및 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 척수손상 관련 질환의 예방 또는 치료용 약학적 조성물
CN105796546B (zh) * 2011-10-18 2020-03-03 株式会社爱茉莉太平洋 包含丁香脂素的sirt1活化剂
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
KR101833460B1 (ko) 2016-07-05 2018-04-13 충남대학교산학협력단 대식세포(macrophage)의 극성(polarization)조절에 의하여 결핵균 생존 및 증식을 억제하기 위한 조성물.
US20200158716A1 (en) * 2017-07-17 2020-05-21 Massachusetts Institute Of Technology Cell atlas of healthy and diseased barrier tissues

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US499355A (en) * 1893-06-13 Machine for making beam-stirrups
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
FR2628425B1 (fr) * 1988-03-08 1992-04-03 Rhone Poulenc Sante Derives d'isoindolinone, leurs procedes de preparation et les medicaments les contenant
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
CA2054339C (en) * 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5177088A (en) * 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
US5969146A (en) 1995-10-11 1999-10-19 Synthelabo Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
JP2002506462A (ja) * 1997-06-26 2002-02-26 イーライ・リリー・アンド・カンパニー 抗血栓物質
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6365370B1 (en) * 1999-09-01 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor

Also Published As

Publication number Publication date
KR20040104613A (ko) 2004-12-10
US20080132481A1 (en) 2008-06-05
US20040006123A1 (en) 2004-01-08
US7169925B2 (en) 2007-01-30
US20040010029A1 (en) 2004-01-15
GB0217920D0 (en) 2002-09-11
KR100972304B1 (ko) 2010-07-26
JP2005529134A (ja) 2005-09-29
TWI296926B (en) 2008-05-21
KR20040106382A (ko) 2004-12-17
TW200408389A (en) 2004-06-01
JP4746271B2 (ja) 2011-08-10

Similar Documents

Publication Publication Date Title
AR039345A1 (es) Derivados de acido amino-1h-indol-2-carboxilico 3-sustituidos y de acido amino-benzo(b)-tiofeno-2-carboxilico 3-sustituidos como inhibidores de la expresion del gen de la inteleuquina-4
CY1111155T1 (el) Ετεροκυκλικοι αναστολεις της μεκ
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
CY1106589T1 (el) (s)-2-ν-προπυλαμινο-5-υδροξυτετραλινη ως d3-αγωνιστικο θεραπευτικο μεσο
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1105301T1 (el) Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
CA2497868A1 (en) Heterocyclic compounds
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
NO20061506L (no) Heterocykliske inhibitorer av MEK og fremgangsmater for anvendelse derav
CY1107080T1 (el) Υποκατεστημενες ινδολο-βασεις του mannich
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
DK1664016T3 (da) Terapeutiske midler, der er anvendelige til behandling af smerter
ATE266007T1 (de) Heterocyclische verbindungen als faktor xa inhibitoren
BR0309188A (pt) Compostos pirazolo como agentes antiinflamatórios e analgésicos
BR0309305A (pt) Compostos de imidazol como agentes antiinflamatórios e analgésicos
SE0104250D0 (sv) Heterocyclic compounds
DE69923444D1 (de) Heterozyklische verbindungen mit faktor xa hemmender wirkung
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav

Legal Events

Date Code Title Description
FB Suspension of granting procedure